Early Identification of T1D: Practical Considerations for Implementation in Clinical Practice

What is the role of early detection of type 1 diabetes and how can it be integrated into clinical practice?

In this episode, our host, Dr. Maha Lebbar, discusses the practical aspects of screening for type 1 diabetes (T1D) with Dr. Rémi Rabasa-Lhoret, endocrinologist at Centre Hospitalier de L’Université de Montréal (CHUM), professor and researcher at the Montréal Clinical Research Institute (IRCM).

Join our experts as they discuss the clinical benefits of early T1D identification and the transformative potential of early interventions in improving long-term health outcomes and preventing severe complications. Learn about the practical steps and options for T1D screening, gaining in-depth insights into various screening pathways, existing programs, and promising research initiatives driving innovation in this field. Tune in as we explore how studies such as FEDERATE Can are actively bridging the critical gap between research and its practical application in clinical settings.

Discover concrete recommendations for healthcare providers to integrate early detection of T1D into their everyday practice, including workflow considerations for screening, monitoring, and follow-up.

Don't miss this discussion!

The opinions and views expressed in this episode are those of the speakers and do not necessarily reflect the position of the entities they represent.

Declaration of conflict of interest:

Dr Maha Lebbar:

• Direct financial links, including receipt of fees: Sanofi. Receipt of grants or funding for research projects or clinical trials: Sanofi.

Dr Rémi Rabasa-Lhoret:

• Direct financial links, including receipt of fees: Abbott, CPD Network, Dexcom, Eli Lilly, Janssen, Medtronic, Merck, Novo Nordisk, Sanofi, Tandem Diabetes Care, Vertex Pharmaceuticals. Advisory Committee or Speaker Bureau Members: 35Pharma Inc., Abbott, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GlaxoSmithKline Inc., HLS Therapeutics, INESSS, Insulet, Medtronic, Merck, Novo Nordisk, Sanofi, Ypsomed. Receipt of grants or funding for research projects or clinical trials: Diabetes Canada, Cystic Fibrosis Canada, Canadian Institutes of Health Research (CIHR), Diabetes Research Foundation (JDRF), Novo Nordisk, Société francophone du diabetes, Medtronic, Merck, Sanofi. Patents relating to a medicine, product or medical device: Eli Lilly.

MAT-CA-2200968